TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25908603
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus bevacizumab 5 mg/kg
Study: 25908603
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus bevacizumab 10 mg/kg
Study: 18504478
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INS)
Study: 27756405
Drug: Active binocular
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active binocular treatment (videogame-based) for 6 weeks
Study: 27756405
Drug: Active binocular
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active binocular treatment (videogame-based)
Study: 7753966
Drug: Ipsapirone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 5 mg administered by mouth three times daily for 14 days
Study: 7753966
Drug: Ipsapirone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone 5 mg
Study: 2113488
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment cycles pooled
Study: 2113488
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy with LA
Study: 2113488
Drug: Serum concentrations
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum concentrations of luteal phase steroids
Study: 365537
Drug: S-carboxy-methyl-cysteine (S.C.M.C.)
Normalized name: S-methyl methanethiosulfonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxy-methyl-cysteine (S.C.M.C.) 3 g/24h
Study: 29463627
Drug: Spironolactone (12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5-50 mg QD)
Study: 29463627
Drug: Clonidine (0.1-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1-0.3 mg BID)
Study: 28078857
Drug: Sevoflurane (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (1% administered immediately after the beginning of cardiopulmonary bypass until the end of treatment)
Study: 17928750
Drug: Duodenoscopic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duodenoscopic infusion of 90 mL of sodium phosphate (NaP) diluted with 180 mL of water (group EA)
Study: 17928750
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered 45 mL of sodium phosphate (NaP) (group OA)
Study: 10915398
Drug: two 160-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 160-mg capsules once daily (OD)
Study: 10915398
Drug: one 160-mg
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 160-mg capsule twice daily (BID)
Study: 8605792
Drug: Lorazepam (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (intermittent intravenous injection, 1.6 +/- 0.1 mg/8 hrs)
Study: 8605792
Drug: Midazolam (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (continuous intravenous infusion, 14.4 +/- 1.2 mg/8 hrs)
Study: 17552048
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus MTX (3 mg/kg)
Study: 17552048
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus MTX (6 mg/kg)
Study: 17552048
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus MTX (3 mg/kg) and (6 mg/kg)
Study: 9611008
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with a combination of cis‐diamminedichloroplatinum (CDDP), vincristine, mitomycin C, and peplomycin (POMP)
Study: 1823658
Drug: Dental fear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental fear treatment
Study: 28697226
Drug: Topical proprietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical proprietary procedural enhancement system (PES) containing a combination of active ingredients including a tripeptide and hexapeptide (TriHex Technology™)
Study: 21259031
Drug: Intravenous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amoxicillin and clavulanic acid (single dose)
Study: 21259031
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo (equal volume, intravenous bolus)
Study: 11549680
Drug: Glucagon-like peptide-1
Normalized name: Glucagon-like peptide-1 (GLP-1) analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide-1 (7-36) amide infusion
Study: 23243254
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (10 mg•kg(‐1) of feed; VE‐10)
Study: 23243254
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (100 mg•kg(‐1) of feed; VE‐100)
Study: 23243254
Drug: Oregano essential
Normalized name: Oregano
DrugBank: Oregano (DB10677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregano essential oil (100 mg•kg(‐1) of feed; OR‐100)
Study: 11289700
Drug: Propylthiouracil (PTU)
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylthiouracil (PTU) 3 x 100 mg/d for 30 d
Study: 3607818
Drug: Pyrethrin-piperonyl-butoxide lotion
Normalized name: piperonyl butoxide / pyrethrins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrethrin-piperonyl-butoxide lotion
Study: 29289531
Drug: GSR biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSR biofeedback therapy
Study: 26551986
Drug: Statin arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin arm (atorvastatin 80 mg/10 mg or simvastatin 20 mg)
Study: 16618298
Drug: Fresh autologous
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh autologous whole blood (15 ml x kg(‐1) collected prior to heparinization)
Study: 16618298
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin (15 ml x kg(‐1) infused intravenously)
Study: 4016054
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyaluronate plus systemic acetazolamide
Study: 29143484
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg d‐1 folate after 4 weeks
Study: 29143484
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg d‐1 folate after 4 weeks
Study: 29143484
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg d‐1 folate after 8 weeks
Study: 29143484
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg d‐1 folate after 8 weeks
Study: 25354015
Drug: Daily online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily online tube potential‐cone beam CT (CBCT) image guidance with reduced CTV2 to PTV2 margins (3 mm)
Study: 17880774
Drug: Thiamphenicol glycinate
Normalized name: thiamphenicol glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol glycinate acetylcisteinate (TGA) 500 mg b.i.d. intramuscularly on the first day and TGA 500 mg b.i.d. by aerosol during the following days (n=151)
Study: 17880774
Drug: Thiamphenicol glycinate
Normalized name: thiamphenicol glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol glycinate acetylcisteinate (TGA) 250 mg b.i.d. by aerosol (n=149)
Study: 17880774
Drug: Other standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other standard antibiotics given intramuscularly (n=268)
Study: 17880774
Drug: Other standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other standard antibiotics given orally (n=249)
Study: 16627794
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril for all, plus indapamide for some)
Study: 14596362
Drug: Candesartan 8/16mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8/16mg and Hydrochlorothiazide 12.5 mg (combination)
Study: 8612863
Drug: IV infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of albumin (n = 13)
Study: 8612863
Drug: IV infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of albumin
Study: 1295286
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide (50 mg, two tablets)
Study: 6540581
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg orally)
Study: 19950090
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg orally for the first four days
Study: 19950090
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg orally from the fifth to the eighth day
Study: 11251731
Drug: Reiki Touch
Normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reiki Touch therapy
Study: 9444543
Drug: Fluoxetine (8-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (8-week treatment)
Study: 25619549
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of an oral loop diuretic at discharge
Study: 25619549
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in loop diuretic dose at discharge for patients already established on diuretics prior to admission
Study: 16446318
Drug: High-dose alkylating
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alkylating chemotherapy (cyclophosphamide, thiotepa and carboplatin)
Study: 16446318
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (FEC followed by radiation therapy and tamoxifen)
Study: 12582945
Drug: Pseudoephedrine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (60 mg four times daily)
Study: 12582945
Drug: Phenylpropanolamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (25 mg four times daily)
Study: 11432680
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single preoperative dose)
Study: 8415806
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (4 g), sardine oil (2.4 g), vitamin E (200 mg) for 4 weeks
Study: 8415806
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil and fish oil treatment
Study: 2877480
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for hypertension
Study: 28282796
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level continuous heat with Ibuprofen (LLCH + IP)
Study: 28282796
Drug: Sham LLCH
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham LLCH with sham Ibuprofen
Study: 25075645
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream 1
Study: 25075645
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream 2
Study: 21610557
Drug: Low-volume ultrasound-guided
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume ultrasound-guided ankle block (16 mL ropivacaine 0.5%)
Study: 21610557
Drug: Conventional-volume surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-volume surface landmark technique (30 mL ropivacaine 0.5%)
Study: 12803865
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) alone (30 mg/kg base given over 3 days)
Study: 12803865
Drug: Chloroquine plus
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine plus ketotifen (CQK) (0.25 mg at presentation followed by 0.125 mg/kg every 8 h for 5 days)
Study: 8851579
Drug: 20% fat
Normalized name: Intralipid 20% Fat Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% fat emulsion formulation (Intralipid; 20% IL)
Study: 8851579
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose (glucose) (5% D) solution
Study: 6720619
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (1 g/day for 8 days)
Study: 30267357
Drug: Local glucocorticoid
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local glucocorticoid (GC) injection combined with local anaesthetic
Study: 28082816
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus NCFM (low-dose)
Study: 28082816
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus NCFM (high-dose)
Study: 11867886
Drug: Vitamin supplements
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplements (folic acid 2 mg, B(6) 25 mg, B(12) 500 mug)
Study: 11210402
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (2.4 g)
Study: 18430053
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day) for 4 months
Study: 18430053
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/day) for 4 months
Study: 16670247
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg memantine twice a day
Study: 15030296
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ACE inhibitors or angiotensin II receptor antagonists and diuretics
Study: 15030296
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors or angiotensin II receptor antagonists alone
Study: 10663453
Drug: Lariam (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lariam (reference formulation)
Study: 1586398
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (calcium, magnesium, potassium, fish oil)
Study: 22187126
Drug: Dose-dense sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense sequential epirubicin 110 mg/m(2) and paclitaxel 250 mg/m(2)
Study: 26164674
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg naltrexone
Study: 17394081
Drug: Calcium polycarbophil
Normalized name: Calcium Polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium polycarbophil (3 g/day) plus bifidobacterium (3 g/day)
Study: 17394081
Drug: Bifidobacterium (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium (3 g/day)
Study: 12087454
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of CMF for patients at least 40 years old with oestrogen-receptor-positive tumours
Study: 12087454
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of CMF for women with oestrogen-receptor-negative tumours
Study: 10215752
Drug: Subcutaneous lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lenograstim (0.5, 2, 5, or 10 microg kg(‐1))
Study: 10215752
Drug: Intravenous lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lenograstim (0.5, 2, 5, or 10 microg kg(‐1))
Study: 10215752
Drug: Subcutaneous lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lenograstim (5 microg kg(‐1))
Study: 10215752
Drug: Intravenous lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lenograstim (5 microg kg(‐1))
Study: 2170718
Drug: 1.0 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microgram dose group
Study: 2170718
Drug: 0.5 microgram
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microgram dose group
Study: 2170718
Drug: 0.25 microgram
Normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 microgram dose group
Study: 374162
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ventolin tablets and Phyllocontin tablets
Study: 374162
Drug: Ventolin tablets
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin tablets
Study: 9240864
Drug: Wide access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Wide access to drugs
Study: 3473681
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy (COAP or MAZE)
Study: 3473681
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of ara‐C
Study: 23344474
Drug: Frequent daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent daily hemodialysis
Study: 22333201
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d) for 12 weeks
Study: 9802618
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen therapy with no irradiation
Study: 9802618
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen therapy with irradiation
Study: 28552806
Drug: Anti-Helicobacter pylori
Normalized name: Anti-Helicobacter pylori IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Helicobacter pylori concomitant therapy
Study: 28552806
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy without probiotics
Study: 26596011
Drug: Postaurical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postaurical injection of methylprednisolone, 40 mg/2 d for 14 d, combined with Ginkgo dipyidamolum and Alprostadil.
Study: 26596011
Drug: Oral prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisone, 1 mg/kg/d for 3 d, if effective, prolonging for another 2 d, combined with Ginkgo dipyidamolum and Alprostadil.
Study: 24132980
Drug: Tasteless solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasteless solution
Study: 16549954
Drug: Drug group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug group (heparin, abciximab, or thrombolytics)
Study: 16549954
Drug: No-drug group
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug group
Study: 16549954
Drug: Drug group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug group (collagen plug devices vs. suture-mediated devices)
Study: 9820297
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interferon beta‐1a 22 microg
Study: 9820297
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interferon beta‐1a 44 microg
Study: 2665546
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with vincristine, prednisone, L-asparaginase, and rubidomycin (Group B, n = 118)
Study: 2665546
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with vincristine, prednisone, and L-asparaginase (Group A, n = 122)
Study: 333084
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg, 6 times per day for 5 days
Study: 19846007
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular therapy only)
Study: 17509028
Drug: Alosetron 0.5
Normalized name: alosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 0.5 mg once daily
Study: 17509028
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg once daily
Study: 17509028
Drug: Alosetron 0.5
Normalized name: alosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 0.5 mg
Study: 14512295
Drug: Daunorubicin with
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin with standard dose of cytarabine
Study: 14512295
Drug: Idarubicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin with standard dose of cytarabine
Study: 14512295
Drug: Mitoxantrone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone with standard dose of cytarabine
Study: 11673750
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg daily for 5 days)
Study: 2774052
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy Maternal Role Preparation Program (4 sessions)
Study: 891483
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg glucagon (G)
Study: 891483
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pethidine plus 0.5 mg atropine (PA)
Study: 28902334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bevacizumab and Triamcinolone
Study: 25185971
Drug: N‐IRI (nimotuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly)
Study: 25185971
Drug: IRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRI (irinotecan 150 mg/m2 biweekly)